Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
L'Oréal to raise €3bn by selling block of shares back to Sanofi
06:38am, Monday, 03'rd Feb 2025
L'Oréal will raise €3 billion by selling 29.6 million Sanofi shares back to Sanofi to cut its stake in the drugmaker. The French cosmetics giant, which also owns Garnier and Lancome, sold the s
Press Release: Sanofi announces buy back of shares from L'Oréal
01:30am, Monday, 03'rd Feb 2025
Sanofi announces buy back of shares from L'Oréal Paris, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L'Oréal.
Agreement Between L'Oréal and Sanofi for the Repurchase by Sanofi of 2.3% of Its Own Shares Held by L'Oréal
01:30am, Monday, 03'rd Feb 2025
AGREEMENT BETWEEN L'ORÉAL AND SANOFI FOR THE REPURCHASE BY SANOFI OF 2.3% OF ITS OWN SHARES HELD BY L'ORÉAL
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Sanofi (SNY) Q4 2024 Earnings Call Transcript
02:41pm, Thursday, 30'th Jan 2025
Sanofi (NASDAQ:SNY ) Q4 2024 Results Conference Call January 30, 2025 9:00 AM ET Company Participants Thomas Larsen - Head of Investor Relations Paul Hudson - Chief Executive Officer Francois Roger -
Sanofi CEO Paul Hudson on RFK Jr.'s vaccine stance
10:30am, Thursday, 30'th Jan 2025
Sanofi CEO Paul Hudson discusses the company's quarterly earnings results and his thoughts on the confirmation hearing of RFK Jr.
Sanofi Misses on Q4 Earnings & Sales, Expects Higher Profits in 2025
09:15am, Thursday, 30'th Jan 2025
SNY misses Q4 earnings and sales estimates. It expects earnings growth to rebound in 2025.
Sanofi CEO Paul Hudson on Q4 results: We've set ourselves up very well for 2025
07:15am, Thursday, 30'th Jan 2025
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, the company's dividend and buyback decision, his thoughts on the confirmatio
Sanofi meets estimates for fourth-quarter profit, plans 5 billion euros in buybacks
01:33am, Thursday, 30'th Jan 2025
French drugmaker Sanofi reported a fourth-quarter profit that came in-line with analysts' estimates on Thursday, and said it would buy back 5 billion euros ($5.21 billion) in shares this year as it se
'The next battleground': Sanofi exploring opportunities in second generation obesity drugs
01:00pm, Thursday, 23'rd Jan 2025
Paul Hudson, CEO of Sanofi, says his firm is exploring the second generation of obesity drugs, noting that solutions for sustained weight loss were "the next battleground."
SNY's Sarclisa Gets EU Nod for Expanded Use in Multiple Myeloma
08:50am, Thursday, 23'rd Jan 2025
The latest decision makes Sanofi's Sarclisa the first anti-CD38 therapy for transplant-ineligible patients with front-line multiple myeloma in the EU.
Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
Press Release: Opella reaches study milestone for Cialis
01:00am, Tuesday, 21'st Jan 2025
Opella reaches study milestone for Cialis Paris, January 21, 2025. Opella, Sanofi's Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on
Sanofi (SYN) CEO Paul Hudson Hosts 43rd Annual J.P. Morgan Healthcare (Transcript)
03:30pm, Tuesday, 14'th Jan 2025
Sanofi (SYN) 43rd Annual J.P. Morgan Healthcare January 14, 2025 12:45 PM ET Company Participants Paul Hudson - Chief Executive Officer Francois-Xavier Roger - Chief Financial Officer Houman Ashrafian
SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)
05:21am, Tuesday, 14'th Jan 2025
Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating relapsed, refractory multiple myeloma.
